To include your compound in the COVID-19 Resource Center, submit it here.

Acorda falls on tozadenant safety concerns

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $11.20 (40%) to $17 on Wednesday after disclosing cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE